Follicular lymphoma stage II Trials in Disease

Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

This trial is testing a new medication called BGB-16673 in combination with other drugs for patients whose B-cell cancer has returned or did not respond to previous treatments. The main investigational drug, BGB-16673, is a BTK-degrader that works by breaking down a specific protein important in B-cell cancers. Depending on which treatment group patients are assigned to, they may also receive other medications such as zanubrutinib, obinutuzumab, glofitamab, or mosunetuzumab.

Who can join this trial:

• Adults aged 18 or older with confirmed B-cell malignancy that has relapsed or is refractory
• Patients who are able to perform daily activities with minimal limitations
• Those with adequate organ and kidney function
• Women who can become pregnant must use effective birth control and have a negative pregnancy test before starting
• Men who are not sterile must also use effective birth control during the study

Who cannot join this trial:

• People under 18 years old
• Those with active cancer involvement in the central nervous system
• Patients with active, uncontrolled infections or significant heart problems
• Those with severe kidney or liver problems
• Pregnant or breastfeeding women
• People with HIV, active hepatitis B or C, or who have had major surgery within 4 weeks
• Those with uncontrolled high blood pressure or other serious medical conditions that could make participation unsafe

The study will be conducted in two parts. The first part will determine the right dose of the drug combinations, while the second part will study how well these doses work and what side effects they may cause. Throughout the trial, doctors will regularly monitor patients' health, check treatment effectiveness through blood tests and examinations, and track any side effects. The goal is to measure how many patients respond to treatment and how long the response lasts.

Study on the Effectiveness and Safety of Golcadomide and Rituximab for Patients with Newly Diagnosed Advanced Follicular Lymphoma

This trial is focused on patients who have been newly diagnosed with advanced stages of the disease. The treatment combines two medications: Golcadomide and Rituximab. Golcadomide is taken orally in capsule form, while Rituximab is given as an infusion directly into the bloodstream through a vein.

Who can join this trial:

• Adults over 18 years of age
• Those newly diagnosed with advanced stage follicular lymphoma
• Patients who meet specific disease characteristics and laboratory values
• Both male and female participants are eligible

Who cannot join this trial:

• Patients who have not been newly diagnosed with advanced stage disease
• Those outside the specified age range
• People who belong to a clinical trial group not included in this study

The main goal of the study is to see if the treatment can achieve a Complete Metabolic Response, which means that after treatment, tests show no signs of cancer in the body. The trial will also monitor for any side effects or adverse events throughout the treatment period. Participants will receive treatment over time, and their response will be evaluated at different stages, such as 6 months and 12 months after starting.

The study will assess the overall response rate, which is the percentage of participants whose cancer shrinks or disappears, as well as progression-free survival and overall survival. Throughout the treatment, additional medications may be introduced, including vincristine sulfate, pegfilgrastim, bendamustine hydrochloride, cyclophosphamide monohydrate, prednisone, and doxorubicin hydrochloride, administered either intravenously or orally depending on the specific drug.